Wave Life Sciences Ltd.
WVE$851M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaSINGAPORE287 employees
Drugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
3
Next Catalyst
This month
Market Overview
Stock performance and key metrics
WVE News
Catalyst Timeline
3 upcoming, 0 past
Phase 2Next
WVE-N531 Phase 2 Est. Readout
June 2026~ConfirmedWVE-N53126
Primary completion for WVE-N531 trial (NCT04906460) in Duchenne Muscular Dystrophy
Source2 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
Drug Pipeline
WVE-006
Alpha-1 Antitrypsin Deficiency
WVE-N531
Duchenne Muscular Dystrophy
SAD: 30mg WVE-003
Huntington Disease
WVE-007
Overweight and Obesity
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
WVE-006 | Phase 2 | Alpha-1 Antitrypsin Deficiency | - | - |
WVE-N531 | Phase 2 | Duchenne Muscular Dystrophy | - | - |
SAD: 30mg WVE-003 | Phase 2 | Huntington Disease | - | - |
WVE-007 | Phase 2 | Overweight and Obesity | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply